The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease-Reference-Cited by-同舟云学术

The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease

Published:2017-04 Issue:4 Volume:11 Page:359-368
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Visanji Naomi P¹,Mollenhauer Brit²,Beach Thomas G³,Adler Charles H⁴,Coffey Christopher S⁵,Kopil Catherine M⁶,Dave Kuldip D⁶,Foroud Tatiana⁷,Chahine Lana⁸,Jennings Danna⁹,

Affiliation:

1. Morton & Gloria Shulman Movement Disorders Centre & Edmund J Saffra program in Parkinson's disease, Toronto Western Hospital, 399 Bathurst Street, MCl 7, Toronto, Ontario, M5T 2S8, Canada

2. Paracelsus-Elena-Klinik, Klinikstrasse 16, 34128 Kassel, Germany

3. Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ 85351, USA

4. Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA

5. Department of Biostatistics, University of Iowa, Iowa City, IA 52242-1409, USA

6. The Michael J Fox Foundation for Parkinson's Research, Grand Central Station, PO Box 4777, New York, NY 10163-4777, USA

7. Department of Medical & Molecular Genetics, Indiana University, Bloomington, IN 46202, USA

8. Department of Neurology, University of Pennsylvania Perelman School of Medicine, 330 South 9th Street, Philadelphia, PA 19107, USA

9. Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA

Abstract

The search for a biomarker for Parkinson's disease (PD) has led to a surge in literature describing peripheral α-synuclein (aSyn) in both biofluids and biopsy/autopsy tissues. Despite encouraging results, attempts to capitalize on this promise have fallen woefully short. The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for PD. S4 will evaluate aSyn in multiple tissues and biofluids within the same subject and across the disease spectrum to identify the optimal biomarker source and provide vital information on the evolution of peripheral aSyn throughout the disease. Additionally, S4 will correlate the systemic aSyn profile with an objective measure of nigrostriatal dopaminergic function furthering our understanding of the pathophysiological progression of PD.

Publisher

Future Medicine Ltd

Subject

Biochemistry, medical,Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2016-0366

Reference66 articles.

1. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia

2. -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies

3. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study

4. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature

5. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical Data;2024-08-08

2. Global biomarker trends in Parkinson's disease research: A bibliometric analysis;Heliyon;2024-03

3. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study;The Lancet Neurology;2023-11

4. The Golgi complex of dopaminergic enteric neurons is fragmented in a hemiparkinsonian rat model;Microscopy Research and Technique;2023-10-19

5. Absence of Alpha-Synuclein Pathology in the Stomach of a Patient With Prodromal Dementia With Lewy Bodies;Journal of Movement Disorders;2023-05-31